Evidence map›Paper›PMID 30650326›Full record

Trial reportThe New England journal of medicine2019

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.

Alejandro Llanos-Cuentas, Marcus V G Lacerda, Tran T Hien, Iván D Vélez, Chayadol Namaik-Larp, Cindy S Chu, Maria F Villegas, Fernando Val, Wuelton M Monteiro, Marcelo A M Brito and 21 more

3 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IIIComparative StudyEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 143 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 14 pooled it
49.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02216123 phase3completednot on this map

A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria

TypeinterventionalSponsorGlaxoSmithKlineRan2015 to 2016Enrolled251ConditionsMalaria, VivaxArmsTafenoquine, Tafenoquine Placebo, Chloroquine, Primaquine, Primaquine Placebo
NCT05203744 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers

TypeinterventionalSponsorNaval Medical Research CenterRan2022 to 2022Enrolled200ConditionsProphylaxisArmsTafenoquine prophylaxis
NCT05690841 phase3recruitingnot on this mapstarted 2024, after this paper: background citation

FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru

TypeinterventionalSponsorUniversity of California, San FranciscoRan2024 to 2027Enrolled7,530ConditionsPlasmodium Vivax Malaria, MalariaArmsFocal Mass Drug Administration (fMDA)
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 14 syntheses or guidelines pooled it, 241 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Tafenoquine: a toxicity overview.Expert opinion on drug safety · 2021
    Pooled it
  12. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.The Cochrane database of systematic reviews · 2020
    Pooled it
  13. Estimating the Proportion ofThe American journal of tropical medicine and hygiene · 2020
    Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Higher-Dose Primaquine to Prevent Relapse ofThe New England journal of medicine · 2022
    Trial
  20. Trial

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 6 institutions in 10 countries.

Alejandro Llanos-CuentasFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Marcus V G LacerdaFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Tran T HienFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Iván D VélezFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Chayadol Namaik-LarpFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Cindy S ChuFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Maria F VillegasFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Fernando ValFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Wuelton M MonteiroFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Marcelo A M BritoFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Mônica R F CostaFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Raul ChuquiyauriFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Martín CasapíaFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Chau H NguyenFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Sandra AruachanFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Ratchadaporn PapwijitsilFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
François H NostenFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Germana BanconeFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Brian AngusFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Stephan DuparcFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Graham CraigFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Victoria M RousellFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Siôn W JonesFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Elizabeth HardakerFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Donna D CloverFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Lindsay KendallFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Khadeeja MohamedFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Gavin C K W KohFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).ORCID 0000-0002-7336-1566
Viviana M WilchesFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
John J BretonFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Justin A GreenFrom Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).
Fundação de Medicina Tropical · BRGlaxoSmithKline (United Kingdom) · GBMahidol University · THUniversidad Peruana Cayetano Heredia · PEAngkor Hospital for Children · KHUniversidad de Antioquia · CO

Funding

University of California Launching Future Leaders in Global Health Research Training ProgramD43TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIG R COHEN, Sung-Jae Lee · 2017 to 2026
$14.7M
6 · The paper itself

Abstract

backgroundTafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure."

methodsWe performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (>3.0 g per deciliter or ≥30% from baseline or to a level of <6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient-level meta-analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per-protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin.

resultsA protocol-defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between-group difference of 1.2 percentage points (95% CI, -4.2 to 5.0). In the patient-level meta-analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96).

conclusionsAmong patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; GATHER ClinicalTrials.gov number, NCT02216123 .).

Indexed as

Plasmodium vivaxAdolescentAdultAminoquinolinesAntimalarialsChloroquineDisease-Free SurvivalDouble-Blind MethodDrug Therapy, CombinationFemaleGlucosephosphate DehydrogenaseGlucosephosphate Dehydrogenase DeficiencyHemoglobinsHumansKaplan-Meier EstimateMalaria, VivaxAminoquinolinesAntimalarialsChloroquineG6PD protein, humanGlucosephosphate DehydrogenaseHemoglobinsPrimaquinetafenoquine

Identifiers

PMID30650326
PMCPMC6657225
OpenAlexW2910452042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.